x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:13:08

ATAC

OncoPharm ·

2020/08/20

Our Landmarks in #OncoPharm Series returns to discuss ATAC: Anastrozole or Tamoxifen Alone or in Combination for adjuvant breast cancer treatment.

en

00:16:24

VIALE-A (venetoclax + azacitidine for elderly/unfit AML)

OncoPharm ·

2020/08/13

VIALE-A: Veneoxlax + azacitidine, a new standard of care for elderly or unfit AML patients, is now published. Lots of supportive care and management concerns to discuss: tumor lysis syndrome, prophylactic anti-microbials, G-CSF use (?), and dose modification for hematologic toxicity. Link: https://doi.org/10.1056/nejmoa2012971

en

00:21:40

New Anti-CD-19 And BCMA Options

OncoPharm ·

2020/08/06

Lots of new options for B-cell malignancies of all ages! We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate). Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.

en

00:11:37

Gemcitabine

OncoPharm ·

2020/07/30

Next up in the Foundations of #OncoPharm series, gemcitabine.

en

00:15:02

Antiemetic & CIPN Guideline Updates

OncoPharm ·

2020/07/23

We summarize the changes to ASCO's latest Antiemetic Guidelines update as well as their guidelines for chemotherapy-induced peripheral neuropathy (CIPN). Then, we take a look at the PO decitabine approval and ponder the question, does low albumin decrease tolerability to some TKIs?

en

00:34:41

Conversation With A Breast Cancer Survivor

OncoPharm ·

2020/07/16

We're joined by Dr. Karen Fancher, oncology pharmacist, to talk about her breast cancer story from diagnosis to shared-decision making treatment plans with her oncologist to treatment toxicity.

en

00:22:17

Neutropenic Fever 101

OncoPharm ·

2020/07/09

While this is a topic best covered with case examples, we do our best to provide the basics in 20 minutes. Experienced clinicians may not be aware of the How Long study briefly discussed in this episode: https://doi.org/10.1016/S2352-3026(17)30211-9

en

00:13:29

Early July FDA Updates

OncoPharm ·

2020/07/02

FDA ended June with 5 new approvals. *selinexor for r/r DLBCL *pembrolizumab for cutaneous squamous cell carcinoma *pembrolizumab for MSI-h/dMMR met. colorectal cancer *avelumab maintenance for met. bladder cancer *SC trastuzumab/pertuzumab/hyaluronidase

en

00:14:26

Clinical Trial Endpoints in Oncology

OncoPharm ·

2020/06/25

A primer on primary endpoints used in oncology clinical trials. Tailored for those new to in-depth evaluations of oncology literature.

en

00:18:12

Lurbinectedin et al

OncoPharm ·

2020/06/18

Topics on this week's Pod include: -Lurbinectedin in SCLC -Nivolumab is esophageal cancer -Pembrolizumab for TMB-high cancers -Gemtuzumab ozogamicin for pediatric AML -Venetoclax + HMA for adult (unfit) AML -Gardasil for prevention of SCCHN -Perhaps the biggest non-oncopharm news of the year?

en

00:12:21

LD Vs Ld

OncoPharm ·

2020/06/11

LD Vs Ld by John Bossaer

en

00:31:21

ASCO 2020

OncoPharm ·

2020/06/04

Recapping lots of updates from ASCO 2020. Then (20:00) we chat with Shannon Hough, oncology pharmacy specialist, to talk about her ASCO abstract (https://meetinglibrary.asco.org/record/185996/abstract) on pharmacist interventions in managing CINV.

en

00:11:07

More NSCLC Updates (Checkmate-9La & ALTA-1L)

OncoPharm ·

2020/05/28

Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC). Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors. (Lots of ASCO talk *next* week!)

en

00:16:29

New Chemo - Free Immunotherapy Options For NSCLC

OncoPharm ·

2020/05/21

There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape. Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.

en

00:29:58

Selpercatinib & More!

OncoPharm ·

2020/05/14

We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target. Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30). Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated

en

00:16:17

Capmatinib & SC Daratumumab

OncoPharm ·

2020/05/08

First, we discuss the FDA approval of daratumumab hyaluronidase for subcutaneous administration and compare its administration to SC administration of rituximab hyaluronidase and trastuzumab hyaluronidase. We end by discussing the 1st FDA-approved drug for MET exon 14 skipping mutations, capmatinib. We also discuss how a receptor tyrosine kinase could skip.

en

00:25:14

Q 6 Pembro, PARP Inhibitors, MonarcHER, Griffin

OncoPharm ·

2020/04/30

Topics of discussion: Q 6 week pembrolizumab dosing schedule FDA approved Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28) The monarcHER study of abemaciclib in HER+ MBC (12:20) The GRIFFIN study of Dara+VRD in myeloma (17:00)

en

00:26:24

Sacituzumab Govitecan, Tucatinib, And More!

OncoPharm ·

2020/04/24

Five (5!) new #oncopharm products to discuss. First, sacituzumab govitecan. Then, (9:30) tucatinib. Finally, (18:40) mitomycin gel, pemitgatinib, and selumetinib.

en

00:20:57

Journal Club: Unscheduled Hydration in Patients...

OncoPharm ·

2020/04/16

Our 1st Journal Club. 1. Read this: https://www.futuremedicine.com/doi/10.2217/fon-2018-0787 2. Ask how, or if, this would change practice. 3. Listen.

en

00:13:02

Bevacizumab's Wild Ride For Metastatic Breast Cancer

OncoPharm ·

2020/04/09

First, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer. Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1). Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs... E2100:

en

423 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter